Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03029351 · ClinicalTrials.gov registry record · Phase 4
GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes
A Phase 4 study, sponsored by University at Buffalo.
- Terminated
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
NCT03029351: Clinical Trial Phase 4 study, sponsored by University at Buffalo.
NCT03029351 is a Phase 4 study that was terminated before completion, run by University at Buffalo. The registered enrollment target is 15 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03029351, a Phase 4 study, was terminated before completion, sponsored by University at Buffalo.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
Study Summary
This is a prospective study to evaluate effect of Exenatide extended release treatment for 1 year on albuminuria levels in T2DM patients with micro- and macroalbuminuria compared to placebo.
Primary Outcome
change from baseline in 24-hr urinary albuminuria (albumin/creatine) level at week 52 following Exenatide extended release OR placebo treatments
Interventions
- DRUG Placebo
- DRUG Exenatide Extended Release for Inj Susp 2 MG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2017-01-10 |
| Est. Completion | 2019-07 |
| Phase | Phase 4 |
Why NCT03029351 stopped before completion
NCT03029351 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03029351 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03029351 about?
NCT03029351 is a clinical study titled "GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes". This is a prospective study to evaluate effect of Exenatide extended release treatment for 1 year on albuminuria levels in T2DM patients with micro- and macroalbuminuria compared to placebo.
What is the current status of trial NCT03029351?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2017-01-10. Estimated completion is 2019-07.
What interventions are being tested in trial NCT03029351?
The interventions under investigation include: Placebo (DRUG), Exenatide Extended Release for Inj Susp 2 MG (DRUG).
Who is sponsoring clinical trial NCT03029351?
This trial is sponsored by University at Buffalo, which has 67 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03029351's enrollment target sits among peer trials
15 1880th of 2000 higher than 100 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI